Myungin Pharm KRX:317450KOSPI
명인제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked8since Sep 11
In Q2 2026, Myungin Pharm reported revenue of ₩76.1bn, up 5.4% year on year, and operating profit of ₩27.6bn. Myungin Pharm (명인제약) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 26 with 2 articles. It was most often mentioned alongside 글로벌테크놀로지 and SK Chemicals.
Filing signals Op. margin 20%+ Dividend grower Screener
Myungin Pharm quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩76.1bn | +5.4% | ₩27.6bn margin 36.3% | ₩24.3bn |
| Q1 2026 | ₩72.1bn | +2.7% | ₩25.1bn margin 34.8% | ₩22.7bn |
| Q4 2025 derived | ₩72.1bn | +5.8% | ₩23.7bn margin 32.8% | ₩23.3bn |
| Q3 2025 | ₩72.7bn | +3.8% | ₩21.9bn margin 30.1% | ₩18.5bn |
| Q2 2025 | ₩72.2bn | – | ₩25.2bn margin 34.8% | ₩21.0bn |
| Q1 2025 | ₩70.3bn | – | ₩21.8bn margin 31.0% | ₩18.6bn |
| Q4 2024 derived | ₩68.1bn | – | ₩21.7bn margin 31.9% | ₩14.0bn |
| Q3 2024 | ₩70.0bn | – | ₩23.3bn margin 33.3% | ₩24.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Myungin Pharm top stories 2 weeks, by number of outlets
- 1
- 2
- 3